Hossein Mokhtari
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hossein Mokhtari has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
Ali Khodadadian
Department of Clinical Biochemistry, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publication- Amir Raoofi
Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
1 shared publication - Atefeh Seghatoleslam
Department of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
1 shared publication - Davood Nasiry
Department of Paramedicine, Amol School of Paramedical Sciences, Mazandaran University of Medical Sciences, Sari, Iran
1 shared publication Elahe Nazari
Department of Biology , Islamic Azad University , Gorgan Branch, Gorgan , Iran
1 shared publicationElham Beyrami Aghbash
Department of Medical Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
1 shared publication
Latest Publications
- 1 October 2023
- Published by Bentham Science Publishers Ltd. in Current Molecular Medicine
- Vol. 23 (8) , 834-841
Cancer Drug Resistance Reduction via Co-treatment with Oxaliplatin and Nitazoxanide: Targeting the ABC Transporters
Object(s): Shortly after cancer is diagnosed, a phenomenon develops in cancer cells called multidrug resistance (MDR), in which cell sensitivity against anti-cancer drugs is significantly reduced. The present investigation aimed to assess the effects of nitazoxanide (NTZ), a safe drug, on LS174T/OXP-resistant cells. Methods: In the current in vitro research, the effects of NTZ and oxaliplatin (OXP) on the viability of LS174T and LS174T/OXP cell lines were evaluated through MTT assay. Then, the changes in expression levels of MDR1, MRP1, BCRP, and LRP genes and proteins were measured by RT-qPCR and western blotting methods, respectively. Lastly, the apoptosis status was assessed by annexin V–FITC/PI staining flow cytometry assay. Results: The IC50 values for cells resistant or sensitive to OXP were revealed (11567 nM vs. 1745 nM; p <0.05 for 24 h incubation, and 5161 nM vs. 882.2 nM; p <0.05 for 48 h incubation). Moreover, NTZ plus OXP led to a leftward shift in the cytotoxicity curve (2004 nM; p = 0.007). This co-treatment significantly decreased the expression of all genes and proteins (p <0.05). Finally, the combination of NTZ and OXP induced a significant increase in apoptosis (p <0.001). Conclusion: The data showed that NTZ treatment could increase the sensitivity of LS174T/OXP cell line to the OXP cytotoxic effects. Thus, NTZ may be efficient in reducing drug resistance in clinics by means of the negative regulation of ATP-binding cassette (ABC) transporters. However, further studies are necessary to explain the exact mechanisms of NTZ.
- 1 October 2023
- Published by Bentham Science Publishers Ltd. in Current Molecular Medicine
- Vol. 23 (8) , 834-841
Cancer Drug Resistance Reduction via Co-treatment with Oxaliplatin and Nitazoxanide: Targeting the ABC Transporters
Object(s): Shortly after cancer is diagnosed, a phenomenon develops in cancer cells called multidrug resistance (MDR), in which cell sensitivity against anti-cancer drugs is significantly reduced. The present investigation aimed to assess the effects of nitazoxanide (NTZ), a safe drug, on LS174T/OXP-resistant cells. Methods: In the current in vitro research, the effects of NTZ and oxaliplatin (OXP) on the viability of LS174T and LS174T/OXP cell lines were evaluated through MTT assay. Then, the changes in expression levels of MDR1, MRP1, BCRP, and LRP genes and proteins were measured by RT-qPCR and western blotting methods, respectively. Lastly, the apoptosis status was assessed by annexin V–FITC/PI staining flow cytometry assay. Results: The IC50 values for cells resistant or sensitive to OXP were revealed (11567 nM vs. 1745 nM; p <0.05 for 24 h incubation, and 5161 nM vs. 882.2 nM; p <0.05 for 48 h incubation). Moreover, NTZ plus OXP led to a leftward shift in the cytotoxicity curve (2004 nM; p = 0.007). This co-treatment significantly decreased the expression of all genes and proteins (p <0.05). Finally, the combination of NTZ and OXP induced a significant increase in apoptosis (p <0.001). Conclusion: The data showed that NTZ treatment could increase the sensitivity of LS174T/OXP cell line to the OXP cytotoxic effects. Thus, NTZ may be efficient in reducing drug resistance in clinics by means of the negative regulation of ATP-binding cassette (ABC) transporters. However, further studies are necessary to explain the exact mechanisms of NTZ.
- 27 December 2022
- Published by Walter de Gruyter GmbH in Hormone Molecular Biology and Clinical Investigation
- Vol. 44 (2) , 181-186
Increased expression of androgen receptor and PSA genes in LNCaP (prostate cancer) cell line due to high concentrations of EGCG, an active ingredient in green tea
Objectives: Androgen receptor (AR) play a key role in the onset and progression of prostate cancer. Epigallocatechin-3-gallate (EGCG) is a polyphenolic compound and the active ingredient in green tea, which is involved in modulating gene expression through epigenetic alterations. Previous studies have shown that EGCG at low concentrations reduces the expression of AR and prostate-specific antigen (PSA) in the LNCaP cell line of prostate cancer. In this study, the effect of higher EGCG concentrations on AR and PSA expression in LNCaP prostate cancer cell line was investigated. Methods: In this study, LNCaP prostate cancer cell line was used and after MTT test, concentrations of 40, 60 and 80 μg/mL EGCG were used for treatment. Then, the expression of AR and PSA genes was evaluated by RT-PCR. AR protein expression was also assessed by Western blotting. Results: The present study showed that treatment of LNCaPs cells by EGCG reduces cell proliferation. The IC50 value was 42.7 μg/mL under experimental conditions. It was also observed that EGCG at concentrations of 40 and 80 μg/mL increased the expression of AR and PSA (p<0.05). Conclusions: The present study showed that the effect of EGCG on AR expression was different at different concentrations, so that unlike previous studies, higher concentrations of EGCG (80 and 40 μg/mL) increased AR and PSA expression. It seems that due to the toxic effects of EGCG in high concentrations on cancer cells and the possibility of its effect on normal cells, more caution should be exercised in its use.
- 27 December 2022
- Published by Walter de Gruyter GmbH in Hormone Molecular Biology and Clinical Investigation
- Vol. 44 (2) , 181-186
Increased expression of androgen receptor and PSA genes in LNCaP (prostate cancer) cell line due to high concentrations of EGCG, an active ingredient in green tea
Objectives: Androgen receptor (AR) play a key role in the onset and progression of prostate cancer. Epigallocatechin-3-gallate (EGCG) is a polyphenolic compound and the active ingredient in green tea, which is involved in modulating gene expression through epigenetic alterations. Previous studies have shown that EGCG at low concentrations reduces the expression of AR and prostate-specific antigen (PSA) in the LNCaP cell line of prostate cancer. In this study, the effect of higher EGCG concentrations on AR and PSA expression in LNCaP prostate cancer cell line was investigated. Methods: In this study, LNCaP prostate cancer cell line was used and after MTT test, concentrations of 40, 60 and 80 μg/mL EGCG were used for treatment. Then, the expression of AR and PSA genes was evaluated by RT-PCR. AR protein expression was also assessed by Western blotting. Results: The present study showed that treatment of LNCaPs cells by EGCG reduces cell proliferation. The IC50 value was 42.7 μg/mL under experimental conditions. It was also observed that EGCG at concentrations of 40 and 80 μg/mL increased the expression of AR and PSA (p<0.05). Conclusions: The present study showed that the effect of EGCG on AR expression was different at different concentrations, so that unlike previous studies, higher concentrations of EGCG (80 and 40 μg/mL) increased AR and PSA expression. It seems that due to the toxic effects of EGCG in high concentrations on cancer cells and the possibility of its effect on normal cells, more caution should be exercised in its use.
- 25 September 2022
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 21 (12) , 6939-6950
Decellularized human amniotic membrane engraftment in combination with adipose‐derived stem cells transplantation, synergistically improved diabetic wound healing
Background: One of the most important and common complications of diabetes is a disorder and defect in diabetic wound healing.Aims: The aim of present study was to investigate the synergistic effects of decellularized human amniotic membrane (dHAM) engraftment and adipose‐derived stem cells (ADSs) transplantation in the healing of delayed and ischemic diabetic wound.Methods: Sixty diabetic male rats were randomly divided into four groups (n = 15), including untreated (Control) group, engraftment by dHAM (dHAM) group, transplanted by ADSs (ADS) group, and engraftment by dHAM plus transplanted by ADSs (dHAM + ADS) group. Sampling was performed on Days 7, 14, and 21 after surgery. Evaluation tests included stereology, immunohistochemistry, molecular, and biomechanical.Results: Our results showed that the wound closure rate, volumes of newly formed epidermis and dermis, density of fibroblasts and blood vessels, collagen deposition, density of proliferation cells, expression levels of TGF‐β and VEGF genes, and biomechanical characteristics were significantly higher in all treated groups compared with control group; however, these changes were considerable in the combination group. This is while that the density of neutrophils and expression levels of TNF‐α and IL‐1β genes in the treated groups, especially in the combination group, were significantly reduced compared with control group.Conclusion: Generally, the simultaneous use of dHAM and ADS accelerates healing and improves the quality of repaired diabetic wounds.
- 25 September 2022
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 21 (12) , 6939-6950
Decellularized human amniotic membrane engraftment in combination with adipose‐derived stem cells transplantation, synergistically improved diabetic wound healing
Background: One of the most important and common complications of diabetes is a disorder and defect in diabetic wound healing.Aims: The aim of present study was to investigate the synergistic effects of decellularized human amniotic membrane (dHAM) engraftment and adipose‐derived stem cells (ADSs) transplantation in the healing of delayed and ischemic diabetic wound.Methods: Sixty diabetic male rats were randomly divided into four groups (n = 15), including untreated (Control) group, engraftment by dHAM (dHAM) group, transplanted by ADSs (ADS) group, and engraftment by dHAM plus transplanted by ADSs (dHAM + ADS) group. Sampling was performed on Days 7, 14, and 21 after surgery. Evaluation tests included stereology, immunohistochemistry, molecular, and biomechanical.Results: Our results showed that the wound closure rate, volumes of newly formed epidermis and dermis, density of fibroblasts and blood vessels, collagen deposition, density of proliferation cells, expression levels of TGF‐β and VEGF genes, and biomechanical characteristics were significantly higher in all treated groups compared with control group; however, these changes were considerable in the combination group. This is while that the density of neutrophils and expression levels of TNF‐α and IL‐1β genes in the treated groups, especially in the combination group, were significantly reduced compared with control group.Conclusion: Generally, the simultaneous use of dHAM and ADS accelerates healing and improves the quality of repaired diabetic wounds.
- Open Access
- 6 September 2016
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 31 (3)
Calculation of LDL‐Cholesterol vs. Direct Homogenous Assay
Background: Low‐density lipoprotein cholesterol (LDLc) can be calculated or measured directly and their accordance is the subject of controversy.Objectives: The aim of this study was to identify the independent predictors of LDLc, to formulate the best equation for calculating LDLc and to evaluate the validity of it and the published formulas, including the new method with adjustable coefficient.Methods: The profile of serum lipids and (apo)lipoproteins of 310 subjects was used to determine the most accurate formula for calculating serum LDLc. Serum lipids, lipoproteins and apolipoproteins were measured by enzymatic, new homogenous and immunoturbidometric methods, respectively.Results: Multiple linear regression analysis indicates that total cholesterol, apoB, HDLc and triglyceride are independent predictors of LDLc. We proposed four new formulas to calculate LDLc. As total cholesterol (TC) is the major determinant of LDLc, it can be estimated simply as 0.545 of total cholesterol. Inclusion of HDLc, triglyceride, apoB and a constant value improved the equation slightly. The equation of: LDLc (mg/dl) = 0.75 TC − 0.5 HDLc − 0.1 TG had the lowest mean and SD of difference among all the methods examined here. LDLc was also calculated by the new modified Friedewald's equation using adjustable factor from Martin's table, but it did not improve the results significantly. LDLc gap was correlated significantly and positively with triglyceride and negatively with cholesterol or its subfractions.Conclusions: Our data suggest the simplest formula: LDLc = 0.545 TC or a more detailed: LDLc = 0.75 TC − 0.5 HDLc − 0.1 TG be used for calculating serum LDLc.
- 6 September 2016
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 31 (3)
Open AccessCalculation of LDL‐Cholesterol vs. Direct Homogenous Assay
Background: Low‐density lipoprotein cholesterol (LDLc) can be calculated or measured directly and their accordance is the subject of controversy.Objectives: The aim of this study was to identify the independent predictors of LDLc, to formulate the best equation for calculating LDLc and to evaluate the validity of it and the published formulas, including the new method with adjustable coefficient.Methods: The profile of serum lipids and (apo)lipoproteins of 310 subjects was used to determine the most accurate formula for calculating serum LDLc. Serum lipids, lipoproteins and apolipoproteins were measured by enzymatic, new homogenous and immunoturbidometric methods, respectively.Results: Multiple linear regression analysis indicates that total cholesterol, apoB, HDLc and triglyceride are independent predictors of LDLc. We proposed four new formulas to calculate LDLc. As total cholesterol (TC) is the major determinant of LDLc, it can be estimated simply as 0.545 of total cholesterol. Inclusion of HDLc, triglyceride, apoB and a constant value improved the equation slightly. The equation of: LDLc (mg/dl) = 0.75 TC − 0.5 HDLc − 0.1 TG had the lowest mean and SD of difference among all the methods examined here. LDLc was also calculated by the new modified Friedewald's equation using adjustable factor from Martin's table, but it did not improve the results significantly. LDLc gap was correlated significantly and positively with triglyceride and negatively with cholesterol or its subfractions.Conclusions: Our data suggest the simplest formula: LDLc = 0.545 TC or a more detailed: LDLc = 0.75 TC − 0.5 HDLc − 0.1 TG be used for calculating serum LDLc.